✦ LIBER ✦

Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab plus docetaxel as primary systemic therapy for breast cancer patients with HER2 overexpression or amplification

✍ Scribed by Saracchini, S.; Foltran, L.; Tuccia, F.; Bassini, A.; Sulfaro, S.; Micheli, E.; Del Conte, A.; Bertola, M.; Gion, M.; Lorenzon, M.; Tumolo, S.

Book ID: 122367885
Publisher: Elsevier Science
Year: 2013
Tongue: English
Weight: 548 KB
Volume: 22
Category: Article
ISSN: 0960-9776
DOI: 10.1016/j.breast.2013.09.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A multicenter, phase II study of epirubi

A multicenter, phase II study of epirubicin/cyclophosphamide followed by docetaxel and concurrent trastuzumab as primary systemic therapy for HER-2 positive advanced breast cancer (the HER2NAT study)

✍ Aogi, Kenjiro; Saeki, Toshiaki; Nakamura, Seigo; Kashiwaba, Masahiro; Sato, Nobu 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 329 KB

A multicenter randomized phase II study

A multicenter randomized phase II study of sequential epirubicin/cyclophosphamide followed by docetaxel with or without celecoxib or trastuzumab according to HER2 status, as primary chemotherapy for localized invasive breast cancer patients

✍ Jean-Yves Pierga; Suzette Delaloge; Marc Espié; Etienne Brain; Brigitte Sigal-Za 📂 Article 📅 2010 🏛 Springer US 🌐 English ⚖ 236 KB

0178 Results of clinical endpoints of a

0178 Results of clinical endpoints of a randomized phase II trial with doxorubicin + pemetrexed followed by docetaxel versus doxorubicin + cyclophosphamide followed by docetaxel as primary systemic therapy for early breast cancer

✍ A. Schneeweiss; A. Ruiz; P. Rovira; A. Bottini; A. Manikhas; J. Wacker; T. Schum 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Phase II Study of Neoadjuvant Docetaxel,

Phase II Study of Neoadjuvant Docetaxel, Vinorelbine, and Trastuzumab Followed by Surgery and Adjuvant Doxorubicin Plus Cyclophosphamide in Women With Human Epidermal Growth Factor Receptor 2–Overexpressing Locally Advanced Breast Cancer

✍ Glück, S. 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 70 KB

Phase I clinical trial of liposomal-enca

Phase I clinical trial of liposomal-encapsulated doxorubicin citrate and docetaxel, associated with trastuzumab, as neo-adjuvant treatment in stages II and IIIA, HER2-overexpressing breast cancer patients. GEICAM 2003-03 study

✍ Anton, A.; Ruiz, A.; Segui, M. A.; Calvo, L.; Munoz, M.; Lao, J.; Sancho, F.; Fe 📂 Article 📅 2009 🏛 Oxford University Press 🌐 English ⚖ 82 KB

Concurrent Bevacizumab with a Sequential

Concurrent Bevacizumab with a Sequential Regimen of Doxorubicin and Cyclophosphamide Followed by Docetaxel and Capecitabine as Neoadjuvant Therapy for HER2− Locally Advanced Breast Cancer: A Phase II Trial of the NSABP Foundation Research Group

✍ Priya Rastogi; Marc E. Buyse; Sandra M. Swain; Samuel A. Jacobs; André Robidoux; 📂 Article 📅 2011 🏛 CIG Media Group, LP. 🌐 English ⚖ 570 KB